Advances in artificial intelligence and machine learning are reshaping biotech, enabling novel protein design, diagnostic testing outside labs, and improved biomarker discovery. The AI-driven AlphaDesign framework accelerates de novo protein creation for therapeutics. Point-of-care devices integrated with AI simplify disease diagnosis without expert intervention. Furthermore, collaborations between biotech firms and AI specialists use virtual models to predict immuno-oncology biomarker responses. However, the rapid rise of AI in drug invention also raises patent quality concerns, as some applications rely heavily on in silico data with limited experimental validation.